Iovance Biotherapeutics, Inc. IOVA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 31.3%-2.9pp | 34.2%+21.1pp | 13.1%— | —— | |
| Operating margin | -153.1%+87.8pp | -240.9%+38,494pp | -38,735%— | —— | |
| Net margin | -148.4%+78.5pp | -226.8%+37,119pp | -37,345.4%— | —— | |
| EBITDA margin | -148.3%+85.2pp | -233.5%+37,533pp | -37,766.7%— | —— | |
| Free cash flow margin | -127.6%+94.3pp | -221.9%+32,083pp | -32,305.3%— | —— | |
| Returns | |||||
| Return on equity | -55.5%+2.0pp | -57.5%+24.4pp | -81.9%-11.3pp | -70.6%-17.1pp | |
| Return on assets | -42.9%+1.1pp | -44%+17.5pp | -61.5%-6.6pp | -54.9%-10.7pp | |
| Return on invested capital | -65.2%+4.6pp | -69.8%+41.7pp | -111.5%-28.6pp | -82.9%-28.4pp | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.1× | 0.2×+0.2× | 0×— | —— | |
| Inventory turnover | 3.5×0.0× | 3.5×— | —— | —— | |
| Liquidity | |||||
| Current ratio | 3.2×-0.5× | 3.7×+0.9× | 2.8×-2.4× | 5.2×-0.5× | |
| Quick ratio | 2.8×-0.5× | 3.3×+0.6× | 2.7×-2.5× | 5.2×-0.5× | |
| Cash ratio | 1.2×+0.2× | 0.9×-0.7× | 1.6×-1.0× | 2.6×+1.7× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.2×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $1.95-20.2% | $2.45-1.4% | $2.49-20.8% | $3.14-22.6% | |
| Valuation | |||||
| Market capitalization | $1.08B-51.9% | $2.26B+8.4% | $2.08B+97.6% | $1.05B-64.9% | |
| Enterprise value | $969.09M-55.9% | $2.2B+11.3% | $1.98B+119% | $900.13M-69.9% | |
| Price / sales | 4.1×-9.6× | 13.7×-1,736× | 1,750.1×— | —— | |
| Price / book | 1.6×-1.6× | 3.2×-0.4× | 3.6×+1.5× | 2.1×-2.7× | |
| EV / sales | 3.7×-9.7× | 13.4×-1,648× | 1,661.4×— | —— | |
| Free cash flow yield | -31%-14.9pp | -16.1%+2.3pp | -18.5%+11.3pp | -29.7%-20.9pp | |
| Earnings yield | -36.1%-19.6pp | -16.5%+4.8pp | -21.3%+16.3pp | -37.6%-26.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s profit margins?
- Iovance Biotherapeutics, Inc. (IOVA) runs a 36.7% gross margin and a -127.2% operating margin, with a -123.9% net margin.
- Where do Iovance Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Iovance Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.